Adjuvant BRAF/MEK Versus Anti-PD-1 in BRAF-Mutant Melanoma: A Propensity Score Matched Survival Analysis

After PSM, no significant differences in outcomes were observed between adjuvant anti-PD-1 and BRAF/MEK-treated patients with stage III BRAF-mutant melanoma.